NASDAQ:CVETCovetrus Stock Price, Forecast & News

Covetrus' stock was trading at $9.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CVET shares have increased by 69.0% and is now trading at $15.28. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Covetrus.

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Covetrus.

Covetrus Inc (NASDAQ:CVET) posted its earnings results on Thursday, May, 14th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.06. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.07 billion. Covetrus had a negative net margin of 24.05% and a positive return on equity of 4.84%. View Covetrus' earnings history.

Covetrus issued an update on its first quarter 2020 Pre-Market earnings guidance on Wednesday, April, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.07-1.07 billion, compared to the consensus revenue estimate of $969.68 million.

4 brokers have issued twelve-month target prices for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.50 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View analysts' price targets for Covetrus.

Media stories about CVET stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Covetrus earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutCovetrus.

Covetrus saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 15,470,000 shares, a decline of 15.0% from the April 15th total of 18,210,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the short-interest ratio is currently 8.7 days. Currently, 15.9% of the company's stock are short sold. View Covetrus' Current Options Chain.

Some companies that are related to Covetrus include Petmed Express (PETS), Rite Aid (RAD), 111 (YI), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), AT&T (T), Verizon Communications (VZ), Evolent Health (EVH), Alphabet (GOOG), IDEXX Laboratories (IDXX), Las Vegas Sands (LVS), Nokia Oyj (NOK) and Pfizer (PFE).

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Covetrus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (10.86%), Morgan Stanley (10.84%), BlackRock Inc. (10.69%), Clayton Dubilier & Rice LLC (9.91%), Clearbridge Investments LLC (3.91%) and State Street Corp (2.51%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan and Timothy Ludlow. View institutional ownership trends for Covetrus.

CVET stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Two Sigma Investments LP, BlackRock Inc., Morgan Stanley, Morgan Stanley, Clayton Dubilier & Rice LLC, Parametric Portfolio Associates LLC, and Gabelli Funds LLC. View insider buying and selling activity for Covetrus.

CVET stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Deutsche Bank AG, State Street Corp, Russell Investments Group Ltd., Westside Investment Management Inc., Aigen Investment Management LP, and Brooktree Capital Management. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan. View insider buying and selling activity for Covetrus.

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CVET stock can currently be purchased for approximately $15.28.

Covetrus has a market capitalization of $1.71 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

The official website for Covetrus is www.henryscheinvet.com.

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]